Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M634Revenue (TTM) $M146Net Margin (%)-12.3Altman Z-Score3.5
Enterprise Value $M493EPS (TTM) $-0.4Operating Margin %-12.7Piotroski F-Score6
P/E(ttm)--Beneish M-Score-2.6Pre-tax Margin (%)-12.3Higher ROA y-yY
Price/Book4.810-y EBITDA Growth Rate %--Quick Ratio3.5Cash flow > EarningsY
Price/Sales4.25-y EBITDA Growth Rate %--Current Ratio3.5Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-8.7Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-14.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M44.4ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with VNDA

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

VNDA is held by these investors:



VNDA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Kelly James PatrickSVP, CFO & Treasurer 2017-01-03Sell10,895$15.51-7.8view
Polymeropoulos Mihael HristosPresident and CEO 2017-01-03Sell23,330$15.48-7.62view
Baroldi PaoloSVP & Chief Medical Officer 2017-01-03Sell16,300$15.51-7.8view
Gulino Richard L.SVP, General Counsel & Sec. 2017-01-03Sell10,900$15.51-7.8view
Flynn James E 2016-09-23Sell1,120,461$16.56-13.65view
Flynn James E 2016-09-19Sell547,886$15.66-8.68view
Polymeropoulos Mihael HristosPresident and CEO 2016-01-04Sell21,353$8.9659.6view
Kelly James PatrickSVP, CFO, Sec & Treasurer 2016-01-04Sell9,564$8.9659.6view
Baroldi PaoloSVP & Chief Medical Officer 2016-01-04Sell12,380$8.9659.6view
Flynn James E 2015-12-16Buy11,170$8.9759.42view

Quarterly/Annual Reports about VNDA:

News about VNDA:

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Cameron International, Envision Healthcare Holdings, Vanda Pharmaceutica Sep 20 2015 
Weekly CEO Sells Highlight: Walker & Dunlop, Arista Networks, Vanda Pharmaceuticals, and Synopsys May 31 2015 
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Best Performing Gurus of Past Six Months are John Paulson, First Eagle and Michael Price Jun 11 2013 
Vanda: This Company Has Great Assets But No Profits Jan 21 2012 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 
Vanda Pharmaceuticals Inc. (VNDA) Acting CFO/Treasurer Stephanie Rast Irish sells 20,000 Shares Feb 23 2010 
Preserving Value: The Case for Voluntary Liquidation Jan 17 2010 

More From Other Websites
VANDA PHARMACEUTICALS INC. Financials Feb 22 2017
Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017 Feb 22 2017
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US :... Feb 21 2017
VANDA PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report Feb 17 2017
Edited Transcript of VNDA earnings conference call or presentation 15-Feb-17 9:30pm GMT Feb 15 2017
Vanda reports 4Q loss Feb 15 2017
Vanda reports 4Q loss Feb 15 2017
Vanda Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Feb 15 2017
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 15 2017
Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results Feb 15 2017
Q4 2016 Vanda Pharmaceuticals Inc Earnings Release - After Market Close Feb 15 2017
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February... Jan 19 2017
Merck KGaA Expands Distribution Deal with Roche (revised) Jan 17 2017
D.C.-area biotech stocks fall on Trump's tough talk on industry Jan 11 2017
Jefferies Has 5 Top Biotech Stocks to Buy for 2017 Jan 10 2017
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 09 2017
Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017... Jan 09 2017
Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US :... Jan 02 2017
Abbott Labs to Close St. Jude Acquisition Later this Week Jan 02 2017
Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate Dec 30 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)